Xenetic Biosciences (XBIO) Competitors $4.29 +0.01 (+0.23%) (As of 12/20/2024 05:17 PM ET) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsSEC FilingsShort InterestTrends XBIO vs. ENLV, AKTX, LSB, CMMB, EQ, PULM, BCTX, LSTA, GOVX, and IBIOShould you be buying Xenetic Biosciences stock or one of its competitors? The main competitors of Xenetic Biosciences include Enlivex Therapeutics (ENLV), Akari Therapeutics (AKTX), Lakeshore Biopharma (LSB), Chemomab Therapeutics (CMMB), Equillium (EQ), Pulmatrix (PULM), BriaCell Therapeutics (BCTX), Lisata Therapeutics (LSTA), GeoVax Labs (GOVX), and iBio (IBIO). These companies are all part of the "pharmaceutical preparations" industry. Xenetic Biosciences vs. Enlivex Therapeutics Akari Therapeutics Lakeshore Biopharma Chemomab Therapeutics Equillium Pulmatrix BriaCell Therapeutics Lisata Therapeutics GeoVax Labs iBio Xenetic Biosciences (NASDAQ:XBIO) and Enlivex Therapeutics (NASDAQ:ENLV) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their valuation, community ranking, risk, earnings, profitability, media sentiment, institutional ownership, dividends and analyst recommendations. Does the MarketBeat Community prefer XBIO or ENLV? Xenetic Biosciences received 119 more outperform votes than Enlivex Therapeutics when rated by MarketBeat users. However, 79.71% of users gave Enlivex Therapeutics an outperform vote while only 67.44% of users gave Xenetic Biosciences an outperform vote. CompanyUnderperformOutperformXenetic BiosciencesOutperform Votes17467.44% Underperform Votes8432.56% Enlivex TherapeuticsOutperform Votes5579.71% Underperform Votes1420.29% Do analysts prefer XBIO or ENLV? Enlivex Therapeutics has a consensus target price of $9.50, suggesting a potential upside of 666.13%. Given Enlivex Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Enlivex Therapeutics is more favorable than Xenetic Biosciences.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Xenetic Biosciences 0 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.00Enlivex Therapeutics 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 1 Strong Buy rating(s) 3.33 Which has stronger valuation & earnings, XBIO or ENLV? Xenetic Biosciences has higher revenue and earnings than Enlivex Therapeutics. Xenetic Biosciences is trading at a lower price-to-earnings ratio than Enlivex Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioXenetic Biosciences$2.52M2.62-$4.14M-$2.66-1.61Enlivex TherapeuticsN/AN/A-$29.07M-$0.98-1.27 Is XBIO or ENLV more profitable? Enlivex Therapeutics has a net margin of 0.00% compared to Xenetic Biosciences' net margin of -161.63%. Xenetic Biosciences' return on equity of -49.51% beat Enlivex Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Xenetic Biosciences-161.63% -49.51% -43.99% Enlivex Therapeutics N/A -67.57%-58.45% Which has more volatility and risk, XBIO or ENLV? Xenetic Biosciences has a beta of 2.24, suggesting that its share price is 124% more volatile than the S&P 500. Comparatively, Enlivex Therapeutics has a beta of 1.01, suggesting that its share price is 1% more volatile than the S&P 500. Do insiders & institutionals believe in XBIO or ENLV? 15.1% of Xenetic Biosciences shares are owned by institutional investors. Comparatively, 1.0% of Enlivex Therapeutics shares are owned by institutional investors. 14.7% of Xenetic Biosciences shares are owned by insiders. Comparatively, 12.3% of Enlivex Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth. Does the media refer more to XBIO or ENLV? In the previous week, Xenetic Biosciences' average media sentiment score of 0.40 beat Enlivex Therapeutics' score of 0.00 indicating that Xenetic Biosciences is being referred to more favorably in the media. Company Overall Sentiment Xenetic Biosciences Neutral Enlivex Therapeutics Neutral SummaryXenetic Biosciences beats Enlivex Therapeutics on 9 of the 17 factors compared between the two stocks. Ad Weiss RatingsNvidia’s Bold Move: Tackling Tech’s $1 Trillion CrisisTaiwan Semiconductor, a partner of Nvidia’s for more than two decades, has seen its shares explode as much as 4,744%. Now, if you’re like everybody else, you want to know what Nvidia’s doing next … and who they’re going to partner with …Find out details on these three critical Nvidia partners immediately. Get Xenetic Biosciences News Delivered to You Automatically Sign up to receive the latest news and ratings for XBIO and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart XBIO vs. The Competition Export to ExcelMetricXenetic BiosciencesPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$6.62M$6.57B$5.12B$9.07BDividend YieldN/A2.98%4.91%4.22%P/E Ratio-1.6110.5991.3417.19Price / Sales2.62195.381,116.59116.80Price / CashN/A57.1642.6437.86Price / Book0.675.104.794.78Net Income-$4.14M$151.51M$120.07M$225.60M7 Day Performance6.98%-2.15%-1.89%-1.24%1 Month Performance10.00%-3.14%11.45%3.36%1 Year Performance30.40%11.50%30.61%16.58% Xenetic Biosciences Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)XBIOXenetic Biosciences1.0536 of 5 stars$4.29+0.2%N/A+33.2%$6.62M$2.52M-1.614Gap DownENLVEnlivex Therapeutics2.323 of 5 stars$1.16-3.3%$9.50+719.0%-36.6%$24.84MN/A0.0070AKTXAkari TherapeuticsN/A$0.99+1.5%N/A-67.2%$24.46MN/A0.009Analyst ForecastGap DownHigh Trading VolumeLSBLakeshore Biopharma0.4996 of 5 stars$2.51+0.8%N/AN/A$23.37M$80.82M0.00773News CoverageGap UpCMMBChemomab Therapeutics3.3189 of 5 stars$1.61+1.9%$7.33+355.5%+230.1%$23.12MN/A-1.5820Positive NewsEQEquillium2.9102 of 5 stars$0.64-9.2%$5.00+681.3%-16.5%$22.68M$45.91M-5.0440Gap DownPULMPulmatrix0.1949 of 5 stars$6.04+5.0%N/A+209.2%$22.06M$10.01M-2.2920Analyst ForecastNews CoverageBCTXBriaCell Therapeutics2.4503 of 5 stars$0.61-7.9%$15.00+2,366.7%-86.3%$22.00MN/A-0.5216Earnings ReportGap UpLSTALisata Therapeutics1.8982 of 5 stars$2.61+1.2%$15.00+474.7%-5.4%$21.91MN/A-1.1030GOVXGeoVax Labs2.9414 of 5 stars$2.29-2.6%$14.20+520.1%-54.8%$21.61M$3.09M0.0017Analyst ForecastNews CoverageIBIOiBio0.9953 of 5 stars$2.35+1.7%$4.30+83.0%N/A$21.50M$175,000.000.00100 Related Companies and Tools Related Companies ENLV Competitors AKTX Competitors LSB Competitors CMMB Competitors EQ Competitors PULM Competitors BCTX Competitors LSTA Competitors GOVX Competitors IBIO Competitors Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:XBIO) was last updated on 12/21/2024 by MarketBeat.com Staff From Our PartnersAmazon coin set to soar 25X – starting December 16th?This tiny 3-cent crypto just partnered with one of the biggest companies in the world… Amazon. And one team...True Market Insiders | SponsoredDid You See Trump’s Bombshell Exec. Order 001?Biden broke it... Now Trump is going to fix it. Starting with "Exec. Order 001."Banyan Hill Publishing | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredThe #1 Crypto for AIWe’ve issued an urgent landmark trade alert for a new crypto wonder. So, I decided to give you this heads-u...Weiss Ratings | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | SponsoredElon Musk’s chilling warning for humanityThe 'invasion' I've discovered has nothing to do with the border crisis. What's happening at our southern bord...The Freeport Society | SponsoredTrump’s Sending THIS Crypto Higher on PurposeDiscover the coin set to explode before 2025! Trump could trigger THIS crypto coin… Crypto 101 Media | SponsoredVladimir Lenin was right…The Magnificent 7 could be in for a world of pain… And the insiders know it. It’s why Jeff Bezos just sold ...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Xenetic Biosciences Inc Please log in to your account or sign up in order to add this asset to your watchlist. Share Xenetic Biosciences With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free XBIO Stock Alerts